STOCK TITAN
  1. Home
  2. News
  3. BMEA

Biomea Fusion Inc - BMEA STOCK NEWS

Welcome to our dedicated news page for Biomea Fusion (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biomea Fusion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biomea Fusion's position in the market.

News
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) granted non-qualified stock options to two new employees for 6,500 shares of common stock. The options will vest quarterly over four years, subject to continued employment. The awards were made under the 2023 Inducement Equity Plan, in compliance with Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.34%
Tags
none
-
News
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
Rhea-AI Summary
Biomea Fusion, Inc. announced positive initial response data from the first two type 1 diabetes patients treated with BMF-219 in the COVALENT-112 study. Both patients showed improved beta-cell function after 4 weeks of dosing. The open-label readout of 40 patients is expected in 2024, with promising results for type 2 diabetes patients as well.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
-
News
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Rhea-AI Summary
Biomea Fusion, Inc. reported positive Phase 2 data for BMF-219 in type 2 diabetes patients, showing continued glycemic control at 26 weeks after dosing cessation. The company aims to deliver short-term treatments to reconstitute insulin-producing beta cells. They also initiated Phase 2 studies in type 1 diabetes and reported promising initial data in AML. Biomea's cash position was $177.2 million at the end of Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
earnings
News
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Rhea-AI Summary
Biomea Fusion, Inc. announces positive results from the COVALENT-111 study at the 17th ATTD Conference, showcasing improved glycemic control in Type 2 Diabetes patients treated with BMF-219. The study indicates enhanced pancreatic islet function with no serious adverse events. The Expansion Phase is enrolling patients for extended treatment periods, aiming to deepen the drug's impact. Biomea plans to present further data at the Q4 2023 Earnings Release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.82%
Tags
none
-
News
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) granted two new employees non-qualified stock options to purchase 7,000 shares of common stock on March 1, 2024. The options will vest quarterly over four years, subject to continued employment. The awards were made under Biomea's 2023 Inducement Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
-
News
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Biomea Fusion, a clinical-stage biopharmaceutical company (Nasdaq: BMEA), announced the expansion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes and the open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024. The company presented proof-of-concept clinical data in a Phase II study with BMF-219 for type 2 diabetes, showing positive results. Additionally, the company received FDA and Health Canada clearance for the initiation of the expansion portion of the Phase II study and the IND/CTA for Phase II study COVALENT-112 of BMF-219 in type 1 diabetes. The company also shared anticipated 2024 milestones for its diabetes and oncology assets and the Biomea FUSION™ Platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
News
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
Rhea-AI Summary
Biomea Fusion, Inc. (BMEA) has announced the dosing of the first patient with type 1 diabetes in the US in its ongoing Phase II study (COVALENT-112) evaluating BMF-219, a novel, investigational covalent menin inhibitor, as a potential treatment for patients with type 1 diabetes. The clinical study aims to regenerate insulin-producing beta cells with the goal of curing diabetes. Data from the Phase II study are expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.36%
Tags
clinical trial
-
News
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that its CEO and Chairman will present at the 42nd Annual J.P. Morgan Healthcare Conference and hold 1x1 meetings. A live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences
-
News
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
Rhea-AI Summary
Biomea Fusion, Inc. (Nasdaq: BMEA) presented positive clinical data for BMF-219, an investigational covalent menin inhibitor, in relapsed/refractory AML patients with menin-dependent mutations at the 65th American Society of Hematology (ASH) Annual Meeting. The clinical update at ASH showed that nearly half of the participants received prior Hematopoietic Stem Cell Transplant, and the median prior lines of therapy was 3. Out of 29 patients dosed in the Phase I of COVALENT-101, 2 Complete Responses (CRs) were observed with a mean time to response of 1.8 months. BMF-219 was generally well-tolerated with no dose-limiting toxicities observed and without treatment discontinuations due to toxicity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.31%
Tags
clinical trial
News
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
Rhea-AI Summary
Biomea Fusion, Inc. (BMEA) announced top line data of the 200 mg dose cohorts from the ongoing Phase II clinical study (COVALENT-111) for BMF-219, a novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes. The 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more, showing promising results in the treatment of diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock BMEA logo
Biomea Fusion Inc

Nasdaq:BMEA

BMEA Rankings

#3209 Ranked by Market Cap
#2016 Ranked by Stock Gains
N/A Ranked by Dividends

BMEA Stock Data

428.88M
19.38M
25.18%
87.06%
36.88%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Redwood City

About BMEA

biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro